Key Points
- Century Therapeutics CEO Brent Pfeiffenberger bought 52,000 shares on Dec. 12 at $0.58 each for $30,160, bringing his direct holdings to 3,322,990 shares (a 1.59% increase).
- Stock and analyst context: IPSC trades around $0.62 with a 52‑week range of $0.34–$1.19 and a market cap of ~$54.4M, has negative EPS, and carries a mixed analyst consensus of "Hold" with a $3.40 target.
Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) CEO Brent Pfeiffenberger acquired 52,000 shares of the firm's stock in a transaction on Friday, December 12th. The stock was purchased at an average price of $0.58 per share, for a total transaction of $30,160.00. Following the completion of the transaction, the chief executive officer directly owned 3,322,990 shares in the company, valued at approximately $1,927,334.20. The trade was a 1.59% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Brent Pfeiffenberger also recently made the following trade(s):
- On Wednesday, November 19th, Brent Pfeiffenberger bought 35,000 shares of Century Therapeutics stock. The shares were purchased at an average price of $0.50 per share, with a total value of $17,500.00.
- On Monday, November 17th, Brent Pfeiffenberger sold 32,456 shares of Century Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $14,605.20.
- On Monday, November 17th, Brent Pfeiffenberger sold 32,456 shares of Century Therapeutics stock. The shares were sold at an average price of $0.45, for a total value of $14,605.20.
Century Therapeutics Stock Performance
Shares of IPSC stock opened at $0.62 on Wednesday. Century Therapeutics, Inc. has a 52-week low of $0.34 and a 52-week high of $1.19. The firm's 50 day moving average price is $0.55 and its two-hundred day moving average price is $0.55. The stock has a market cap of $54.41 million, a PE ratio of -1.95 and a beta of 1.80.
Century Therapeutics (NASDAQ:IPSC - Get Free Report) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.07. Century Therapeutics had a negative net margin of 19.10% and a negative return on equity of 10.01%. As a group, sell-side analysts predict that Century Therapeutics, Inc. will post -1.61 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Century Therapeutics
A number of large investors have recently bought and sold shares of IPSC. Prudential Financial Inc. acquired a new stake in shares of Century Therapeutics in the second quarter valued at approximately $25,000. Qube Research & Technologies Ltd acquired a new position in Century Therapeutics during the second quarter worth $38,000. Y Intercept Hong Kong Ltd bought a new position in Century Therapeutics in the second quarter valued at $50,000. Raymond James Financial Inc. acquired a new stake in Century Therapeutics in the 2nd quarter valued at $51,000. Finally, AQR Capital Management LLC increased its stake in Century Therapeutics by 358.9% in the 1st quarter. AQR Capital Management LLC now owns 111,079 shares of the company's stock valued at $53,000 after buying an additional 86,875 shares during the last quarter. Institutional investors and hedge funds own 50.20% of the company's stock.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on the company. Wall Street Zen cut Century Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, October 20th. Leerink Partners reiterated a "market perform" rating and issued a $2.00 price target (down previously from $7.00) on shares of Century Therapeutics in a report on Monday, November 17th. Weiss Ratings reissued a "sell (e+)" rating on shares of Century Therapeutics in a research report on Wednesday, October 8th. Finally, Leerink Partnrs cut shares of Century Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, November 17th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $3.40.
View Our Latest Stock Report on Century Therapeutics
About Century Therapeutics
(
Get Free Report)
Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
